🕵️ Inhibikase Therapeutics, Inc. ($IKT)
SEC insider & ownership activity, last 12 months · CIK 1750149 · every row links its SEC filing
Insider buy value was withheld pending verification over the last 12 months. No red-flag 8-Ks in the window.
Insider flow
1 buyer, value withheld pending verification (1 lots) · 0 sellers, $0 (0 lots)
| Insider | Buys | Bought | Sells | Sold | Last |
|---|---|---|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 1 | value withheld pending verification | 0 | – | Nov 21, 2025 |
5%+ holders
| Holder | Stake | Class | Schedule | Event | |
|---|---|---|---|---|---|
| Commodore Capital LP | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Commodore Capital Master LP | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Robert Egen Atkinson | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Michael Kramarz | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| RA Capital Management, L.P. | 9.9% | 13G | Jul 31, 2026 | filing ↗ | |
| Peter Kolchinsky | 9.9% | 13G | Jul 31, 2026 | filing ↗ | |
| Rajeev Shah | 9.9% | 13G | Jul 31, 2026 | filing ↗ | |
| RA Capital Healthcare Fund, L.P. | 9.9% | 13G | Jul 31, 2026 | filing ↗ | |
| ADAR1 Capital Management, LLC | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Daniel Schneeberger | 9.9% | 13G | May 15, 2026 | filing ↗ | |
| Fairmount Funds Management LLC | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| Fairmount Healthcare Fund II L.P. | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| Peter Harwin | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| Tomas Kiselak | 9.9% | 13G | Feb 17, 2026 | filing ↗ | |
| Sands Capital Life Sciences Pulse Fund II, L.P. | 9.3% | 13G | Aug 13, 2026 | filing ↗ | |
| Sands Capital Alternatives, LLC | 9.3% | 13G | Aug 13, 2026 | filing ↗ | |
| Frank M. Sands | 9.3% | 13G | Aug 13, 2026 | filing ↗ | |
| ADAR1 Capital Management GP, LLC | 8.5% | 13G | May 15, 2026 | filing ↗ | |
| Perceptive Advisors LLC | 6.9% | 13G | Aug 14, 2026 | filing ↗ | |
| Joseph Edelman | 6.9% | 13G | Aug 14, 2026 | filing ↗ | |
| Perceptive Life Sciences Master Fund, Ltd. | 6.9% | 13G | Aug 14, 2026 | filing ↗ | |
| Trails EDGE Capital Partners, LP | 6.1% | 13G | May 15, 2026 | filing ↗ | |
| Trails EDGE Biotechnology Master Fund, LP | 6.1% | 13G | May 15, 2026 | filing ↗ | |
| Ortav Yehudai | 6.1% | 13G | May 15, 2026 | filing ↗ | |
| BlackRock, Inc. | 5.9% | 13G | Jul 28, 2026 | filing ↗ |
Planned insider sales (Form 144)
No sale notices filed in the last 12 months.
Material events (8-K)
| Item | Event date | |
|---|---|---|
| Reg FD disclosure (7.01) | Sep 8, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Sep 8, 2026 | filing ↗ |
| Auditor change (4.01) | Aug 21, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 21, 2026 | filing ↗ |
| Earnings (2.02) | Aug 11, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Aug 11, 2026 | filing ↗ |
| Unregistered equity sale (3.02) | Jul 29, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 29, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Jul 23, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 23, 2026 | filing ↗ |
| Other events (8.01) | Jul 14, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jul 14, 2026 | filing ↗ |
| Officer/director changes (5.02) | Jun 26, 2026 | filing ↗ |
| Charter/bylaw changes (5.03) | Jun 26, 2026 | filing ↗ |
| Shareholder vote (5.07) | Jun 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Jun 26, 2026 | filing ↗ |
| Earnings (2.02) | May 12, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | May 12, 2026 | filing ↗ |
| Reg FD disclosure (7.01) | Apr 7, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Apr 7, 2026 | filing ↗ |
| Earnings (2.02) | Mar 26, 2026 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Mar 26, 2026 | filing ↗ |
| Other events (8.01) | Dec 19, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Dec 19, 2025 | filing ↗ |
| Material agreement (1.01) | Nov 20, 2025 | filing ↗ |
| Other events (8.01) | Nov 20, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 20, 2025 | filing ↗ |
| Other events (8.01) | Nov 20, 2025 | filing ↗ |
| Financial Statements and Exhibits (9.01) | Nov 20, 2025 | filing ↗ |
| Earnings (2.02) | Nov 14, 2025 | filing ↗ |